Patents by Inventor Matthew Cullen

Matthew Cullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12319698
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: June 3, 2025
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Publication number: 20250108167
    Abstract: A system for mixing and delivering content is disclosed. The system includes an applicator, a needle assembly, and a micro seal. The applicator includes two component chambers separate from one another, each component chamber including at least one output port on a distal end thereof and an applicator hub disposed on a distal end of the applicator adjacent to the at least one output port of each component chamber. The needle assembly includes an elongate hollow stylet having a plurality of lumens therein and a needle hub having an interior cannula fluidly coupled to the elongate hollow stylet. The micro seal is disposed within the applicator hub. The micro seal is configured to receive the interior cannula of the needle hub to establish a fluid coupling between each of the two component chambers with a respective one of the lumens within the elongate hollow stylet.
    Type: Application
    Filed: September 27, 2024
    Publication date: April 3, 2025
    Applicant: CLEARSTREAM TECHNOLOGIES LIMITED
    Inventors: Matthew Cullen, Victor Bell
  • Patent number: 12180189
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: December 31, 2024
    Assignee: Kineta, Inc.
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Publication number: 20240335611
    Abstract: A component delivery system is disclosed. The component delivery system includes an applicator including two chambers separate from one another, each chamber including at least one output port on a distal end thereof for receiving corresponding pistons. The component delivery system further includes a two-piece alignment fixture removably couplable to the applicator and a two-piece piston insert removably couplable to the pistons, the two-piece piston insert engagable with the two-piece alignment fixture to prevent removal of the pistons from the two chambers.
    Type: Application
    Filed: June 20, 2024
    Publication date: October 10, 2024
    Applicant: CLEARSTREAM TECHNOLOGIES LIMITED
    Inventors: Matthew Cullen, Dylan Beyhl, Jordan P. Addison, Victor Bell
  • Patent number: 11958873
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 16, 2024
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Publication number: 20240116894
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: July 12, 2023
    Publication date: April 11, 2024
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Patent number: 11746098
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 5, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Publication number: 20230242557
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 3, 2023
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Publication number: 20230183256
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: November 18, 2022
    Publication date: June 15, 2023
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Patent number: 11560385
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 24, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Publication number: 20220298181
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 22, 2022
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Patent number: 11242361
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Publication number: 20210188802
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Publication number: 20210115057
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Patent number: 10899751
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • Publication number: 20200308198
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Publication number: 20200299270
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: November 21, 2019
    Publication date: September 24, 2020
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Patent number: 10532996
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 14, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Publication number: 20200010461
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 9, 2020
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • Publication number: 20180310046
    Abstract: A content distribution system featuring a plurality of wearable display devices. Wherein the wearable display devices may display be updated in real time via data connection with content from advertisers or other organizations.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventor: Matthew Cullen